Nitric oxide synthesized by inducible nitric oxide synthase (iNOS) has been implicated as a mediator of inflammation in rheumatic and autoimmune diseases. We report that exposure of lipopolysaccharide-stimulated murine macrophages to therapeutic concentrations of aspirin (IC50 = 3 mM) and hydrocortisone (IC50 = 5 ,uM) inhibited the expression of iNOS and production of nitrite. In contrast, sodium salicylate (1-3 mM), indomethacin (5-20 ,uM), and acetaminophen (60-120 ,uM) had no significant effect on the production of nitrite at pharmacological concentrations. At suprapharmacological concentrations, sodium salicylate (IC50 = 20 mM) significantly inhibited nitrite production.
expression of iNOS and production of nitrite. In contrast, sodium salicylate (1-3 mM), indomethacin (5-20 ,uM) , and acetaminophen (60-120 ,uM) had no significant effect on the production of nitrite at pharmacological concentrations. At suprapharmacological concentrations, sodium salicylate (IC50 = 20 mM) significantly inhibited nitrite production.
Immunoblot analysis of iNOS expression in the presence of aspirin showed inhibition of iNOS expression (IC5s = 3 mM). Sodium salicylate variably inhibited iNOS expression (0-35%), whereas indomethacin had no effect. Furthermore, there was no significant effect of these nonsteroidal antiinflammatory drugs on iNOS mRNA expression at pharmacological concentrations. The effect of aspirin was not due to inhibition of cyclooxygenase 2 because both aspirin and indomethacin inhibited prostaglandin E2 synthesis by >75%. Aspirin and N-acetylimidazole (an effective acetylating agent), but not sodium salicylate or indomethacin, also directly interfered with the catalytic activity of iNOS in cell-free extracts. These studies indicate that the inhibition of iNOS expression and function represents another mechanism of action for aspirin, if not for all aspirin-like drugs. The effects are exerted at the level of translational/posttranslational modification and directly on the catalytic activity of iNOS.
Nitric oxide (NO), first identified as an endothelium-derived relaxation factor (1) , is now recognized to be an intra-and extracellular mediator of cell function (2) (3) (4) (5) . NO produced by the constitutive isoform of nitric oxide synthase (NOS) is a key regulator of homeostasis, whereas the generation of NO by inducible NOS (iNOS) plays an important role in inflammation, host-defense responses, and tissue repair (2) (3) (4) . NO formation is increased during inflammation (rheumatoid arthritis, and ulcerative colitis, Crohn disease), and several classic inflammatory symptoms (erythema and vascular leakiness) are reversed by NOS inhibitors (2-4). Vane and coworkers (6) have implicated NO as an important mediator of inflammation in animal models. Furthermore, because iNOS is up-regulated by endotoxin, interleukin 1, tumor necrosis factor, and interferon y, the increased synthesis of NO has been implicated in autoimmune diseases, allograft rejection, graft-versus-host disease, and systemic response to sepsis. Recent studies by Salvemini et al. (7) have shown that NO modulates the activity of prostaglandin endoperoxide H synthase 2 [cyclooxygenase 2 (COX-2)] in a concentrationdependent manner, through a mechanism independent of cGMP.
Although nonsteroidal antiinflammatory drugs (NSAIDs) clearly inhibit the synthesis and release of prostaglandins (8, 9) , these actions are by no means sufficient to explain all the antiinflammatory effects of NSAIDs. NSAIDs also inhibit activation of neutrophils (10) , which provoke inflammation by releasing products other than prostaglandins (11) . In these studies we examined the effect of NSAIDs on NO production.
Among the agents studied in an effort to elucidate the effect of NSAIDs on iNOS expression and function, we have selected three: an acetylated salicylate (aspirin, an effective inhibitor of COX); a nonacetylated salicylate (sodium salicylate, an ineffective inhibitor of COX); and a nonacetylated nonsteroidal compound (indomethacin, a potent inhibitor of COX). We tested the hypothesis that NSAIDs, which inhibit COX activity, might inhibit inflammation by modifying iNOS expression/ activity. Aspirin, sodium salicylate, and indomethacin, which reach therapeutic concentrations in plasma of 1-3 mM, 1-3 mM, and 5-20 ,uM, respectively (12), were tested for their capacities to inhibit iNOS expression/catalytic activity at the clinically relevant concentrations. In the present study we report that aspirin and, to a lesser extent, sodium salicylate (but not indomethacin) inhibit iNOS expression in murine macrophages activated with lipopolysaccharide (LPS). In addition, aspirin inhibits the catalytic activity of iNOS, an effect mimicked by N-acetylimidazole (NAI), another acetylating agent. We therefore conclude that the aspirin-like drugs differ in their mode of action and that acetylation may be a critical difference. Assay for COX-2 in Whole Cells. Cells were incubated with LPS (1 ,ug/ml) for 16 hr to induce COX-2, exposed to NSAIDs for 1 hr, and subsequently harvested. The harvested cells were then incubated with radiolabeled arachidonic acid (100,000 cpm, 57 mCi/mM) in 1 ml of Tris HCl (together with 3 ,uM of cold arachidonic acid) for 10 min. Specific enzyme activity (whole-cell assays) was measured by the conversion of [14C]arachidonic acid to prostaglandin E2 after separation by TLC (6, 17) . Authentic prostaglandin and monohydroxy standards were run in parallel. The transformed products were quantitated by a Bioscan system 200 imaging scanner, as described above.
MATERIALS AND METHODS

RESULTS AND DISCUSSION
Effects of NSAIDs on Nitrite Accumulation. Murine macrophage cells (RAW 264.7) were selected because the iNOS regulation in these cells has been well-characterized, both at the biochemical and molecular levels (2, 18, 19) . RAW 264.7 cells were activated with LPS at 100 ng/ml to induce iNOS (18) with and without aspirin (1-3 mM), sodium salicylate (1-3 mM), and indomethacin (5-20 ,uM) . Expression and activity of iNOS were monitored by estimating the stable end-product nitrite, as described for these cells by other investigators (7, 18, 19) . (5 ,uM) did not significantly inhibit nitrite production (-7%). Suprapharmacological concentrations of sodium salicylate (5 mM) inhibited nitrite accumulation by 15% under identical conditions. However, the IC50 of sodium salicylate with respect to nitrite accumulation was 20 mM, whereas its ability to inhibit fMet-Leu-Phe-induced neutrophil aggregation was 3 mM (data not shown) (11) . Although indomethacin is effective therapeutically at 20 ,M, the extent to which it inhibited nitrite accumulation (10 ± 9.6%) was only marginally greater than that seen with 5 ,zM and was not statistically significant. Our results on the effect of indomethacin on nitrite accumulation in RAW 264.7 cells were identical to those seen by Salvemini et al. (7) . Acetaminophen (60-120 ,uM), an analgesic agent closely related to salicylates, failed to block nitrite production (1 ± 1%) in LPS-stimulated macrophages at therapeutic concentrations. As previously shown by Moncada and coworkers (21) in murine macrophages (J774 cells) and as seen here (Table 2) , hydrocortisone (5 ,uM) inhibited endotoxin-induced NO production by >60%. Murine macrophage cells (RAW 264.7) were incubated with NSAIDs for 2 hr followed by addition of LPS at 100 ng/ml. After 16-18 hr of incubation, the medium was used to estimate nitrite accumulation by the modified Greiss method (20) . Specific activity of iNOS was determined in cell-free extracts at a given time, as described. Nitrite and specific activity data are representative of means ± SD values, as determined by Student's t test, for four independent experiments. The P values indicate comparisons with LPS-stimulated cells. We next compared the capacities of selected drugs to inhibit the specific activity of COX-2 in RAW 264.7 cells exposed to LPS, as shown in Table 2 . Aspirin (3 mM) and indomethacin (20 ,M) inhibited the specific activity of COX-2 by 79 ± 6.7% (P <0.001) and 84 ± 4.0% (P <0.002), respectively, whereas sodium salicylate (3 mM) had no effect [16 ± 11% (P <0.28)].
These data indicate that aspirin does not inhibit nitrite production by inhibiting COX because aspirin shares this latter effect with indomethacin.
We further examined the mechanism of action of aspirin by determining its effects on (i) the specific activity of the enzyme, (ii) the synthesis of iNOS at the protein level, (iii) the synthesis of mRNA, and (iv) the catalytic activity of iNOS in cell-free extracts and also by comparing it with sodium salicylate and indomethacin.
Effect of NSAIDs on Expression and Catalytic Activity of iNOS. Because nitrite accumulation, which represents the cumulative effect of iNOS expression from induction of the enzyme, does not directly assess the effects of pharmacologic agents (i.e., NSAIDs) on specific enzyme activity, we analyzed these two parameters in tandem.
The specific enzyme activity of iNOS from cells exposed to aspirin in cell-free extracts showed a significant inhibition in activity in a dose-dependent fashion (IC50 = 3 mM). Sodium salicylate and indomethacin did not inhibit the specific activity of iNOS ( (7). Indomethacin (5 ,uM) inhibited COX-2 activity by >75% but had no effect on iNOS expression in immunoblot analysis (Fig. 1A) Kopp and Ghosh (24) showed that aspirin (3 mM) or sodium salicylate (5 mM) inhibit NF-KB-dependent transcription, using sensitive assays based on plasmids containing two IgK-KcB sites driving a luciferase reporter gene. However, in the same studies, the same concentrations of aspirin and sodium salicylate had no significant effect on NF-KB activation, judged by gel-shift assays. Nathan and coworkers (19) Similarly, 5 ,LM indomethacin or an equivalent volume of absolute alcohol had no effect (Fig. 2) . These studies demonstrated that aspirin, but not sodium salicylate or indomethacin, directly interfered with the catalytic activity of iNOS, possibly by acetylating an important functional component of the enzyme or its cofactors. However, because sodium salicylate at therapeutic (2 mM) and suprapharmacological (5 and 20 mM) concentrations inhibits accumulation of nitrite (by 6%, 15%, and 50%, respectively) and has only minimal and insignificant effect on the expression of the iNOS protein, the possibility of sodium salicylate interfering with iNOS catalytic activity at suprapharmacological concentrations cannot be ruled out.
Effect the catalytic activity of iNOS in cell-free extracts and compared it with equivalent amounts of aspirin in the same experiment. Fig. 3 shows the dose-dependent inhibition of iNOS by NAI and aspirin. In contrast to aspirin, which does not seem to inhibit the iNOS activity significantly (10-12%) at 0.1 mM (Figs. 2 and 3 ), NAI at similar concentrations inhibited -45% of iNOS activity. However, at 1 mM, aspirin and NAI inhibited the catalytic activity of iNOS by 45% and 74%, respectively, whereas imidazole at similar concentrations had no significant effect (<5% inhibition). These experiments further indicate that acetylation of iNOS [and/or essential cofactor(s)] inactivates its catalytic activity and that the potency of NAI is relatively greater than that of aspirin. NAI, which is commonly used for acetylation of tyrosine hydroxyl (28) (29) (30) , acetylates protein residues at rates proportional to their nucleophilicity and accessibility (27, 28) .
These observations may explain the different potency of aspirin and sodium salicylate. Aspirin inhibits iNOS by effects on both synthesis of the iNOS protein and on the catalytic activity of the enzyme, possibly by acetylation of the enzyme and/or an essential cofactor, whereas indomethacin and sodium salicylate (which weakly inhibits iNOS protein expression) have no significant effect on the catalytic activity of iNOS. However, the possibility that aspirin interferes in the biosynthesis of other crucial cofactors cannot be excluded (3, 4) .
In separate studies, we observed that the effects of aspirin are not restricted to murine macrophages. Slices of human osteoarthritic cartilage, in contrast with normal human cartilage, showed up-regulated NOS and accumulated >70 ,uM of nitrite in the medium, enough to damage tissue (31) . Addition of 2 mM aspirin suppressed nitrite accumulation by at least 50% in ex vivo experiments (unpublished data), thus indicating that human chondrocyte NOS (which appears to be distinct from murine iNOS) is sensitive to aspirin and may also be sensitive to other NSAIDs.
It is clear from these experiments that aspirin does not inhibit iNOS expression completely at the therapeutic concentrations selected. However, partial suppression of iNOS may be sufficient to inhibit an inflammatory response. This assumption is supported by studies in animal models, where partial inhibition of NOS by NOS inhibitors in rats with induced adjuvant arthritis was sufficient to reduce paw swelling (indicating reduction in inflammation) without significantly affecting the elevated excretion of nitrite in the urine (32) . Thus, small reductions in NO levels may profoundly affect the process of inflammation, and aspirin-like agents that incompletely inhibit iNOS expression at therapeutic concentrations may still be good candidates for pharmaceutical intervention to modulate iNOS. These data also show that at equivalent therapeutic levels, salicylates and indomethacin have divergent effects on iNOS. Such observations are consistent with previous studies that have shown important differences among NSAIDs with regard to their capacities to inhibit neutrophil function (11) , COX-2 activity (17), NF-KB activation (24) , and neurogenic inflammation (15) .
In summary, we conclude that the inhibition of iNOS expression/function represents another mechanism of action for aspirin-like drugs and may explain individual differences in response to NSAIDs in patients with inflammatory diseases. In addition, a search for agents that can acetylate iNOS or its cofactors may be an important pharmacological strategy for developing newer aspirin-like drugs.
